AR007096A1 - Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas - Google Patents
Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticasInfo
- Publication number
- AR007096A1 AR007096A1 ARP970101976A ARP970101976A AR007096A1 AR 007096 A1 AR007096 A1 AR 007096A1 AR P970101976 A ARP970101976 A AR P970101976A AR P970101976 A ARP970101976 A AR P970101976A AR 007096 A1 AR007096 A1 AR 007096A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- activity
- pharmaceutical compositions
- formula
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Presenta compuestos que tienen la fórmula (I), donde y es 0, 2 o 3; r es 0-6, Z es (CH2)7- o (CH2)e-C6H4-(CH2)f o donde e es 0-1 y f es 1-6; R15 esH, -Cl, -OMe o de fórmula (II), donde n es 0-4, R17 es C2H5, -alilo, o -bencilo, y R16 esd e fórmula (III), donde t es 0-1, x es 0-4 y R4 es unode los siguientes: haluro, alquilo de 1 a 6 carbonos, OR, NR2, NO2(R=H o alquilo de 1 a 6 carbonos). Estos compuestos son útiles para inhibir lasmetaloproteasas de matriz y, por lo tanto,pa ra combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritisreumatoidea, la artritits séptica, las enfermedades periodontales, las úlceras de córnea, la proteinuria, la enfermedad deaneurisma a órtico, laepidermólisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osteopenias en las que media la actividad de MMP, laenfermedad de la articulación temporomandibular, las enfermedades desmielin izantes del sistema nervioso; las metástasis de tumores o lapérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura de placa ateroesclerótica.Asimismo se relacionacon un método para inhibir su actividad, con composiciones farmacéuticas y uso de dichos compuestos para prepararcomposiciones farmacéuticas que comprenden una cantidad de un compuesto que sea eficaz para inhibir la actividad de porlo menos una m etaloproteasa dematriz.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64838496A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007096A1 true AR007096A1 (es) | 1999-10-13 |
Family
ID=24600568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101976A AR007096A1 (es) | 1996-05-15 | 1997-05-12 | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0912487A1 (es) |
| JP (1) | JP3417951B2 (es) |
| CN (1) | CN1163466C (es) |
| AR (1) | AR007096A1 (es) |
| AU (1) | AU727648B2 (es) |
| CA (1) | CA2253869C (es) |
| CO (1) | CO4990925A1 (es) |
| HR (1) | HRP970246B1 (es) |
| ID (1) | ID20291A (es) |
| MY (1) | MY132470A (es) |
| PA (1) | PA8429401A1 (es) |
| PE (1) | PE65998A1 (es) |
| SV (1) | SV1997000034A (es) |
| TN (1) | TNSN97085A1 (es) |
| TW (1) | TW467892B (es) |
| WO (1) | WO1997043238A1 (es) |
| YU (1) | YU18797A (es) |
| ZA (1) | ZA974032B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| EP2184284B1 (en) * | 2007-08-15 | 2013-04-10 | Kyorin Pharmaceutical Co., Ltd. | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| CN106661008A (zh) | 2014-04-03 | 2017-05-10 | 拜耳制药股份公司 | 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸 |
| US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE185798T1 (de) * | 1994-01-22 | 1999-11-15 | British Biotech Pharm | Metalloproteinaseinhibitoren |
-
1997
- 1997-05-09 ZA ZA9704032A patent/ZA974032B/xx unknown
- 1997-05-09 TN TNTNSN97085A patent/TNSN97085A1/fr unknown
- 1997-05-09 MY MYPI97002045A patent/MY132470A/en unknown
- 1997-05-09 HR HR970246A patent/HRP970246B1/xx not_active IP Right Cessation
- 1997-05-09 CO CO97025164A patent/CO4990925A1/es unknown
- 1997-05-12 PE PE1997000362A patent/PE65998A1/es not_active Application Discontinuation
- 1997-05-12 AU AU31219/97A patent/AU727648B2/en not_active Ceased
- 1997-05-12 PA PA19978429401A patent/PA8429401A1/es unknown
- 1997-05-12 SV SV1997000034A patent/SV1997000034A/es not_active Application Discontinuation
- 1997-05-12 EP EP97926454A patent/EP0912487A1/en not_active Withdrawn
- 1997-05-12 YU YU18797A patent/YU18797A/sr unknown
- 1997-05-12 AR ARP970101976A patent/AR007096A1/es unknown
- 1997-05-12 WO PCT/US1997/007975 patent/WO1997043238A1/en not_active Application Discontinuation
- 1997-05-12 JP JP54100297A patent/JP3417951B2/ja not_active Expired - Fee Related
- 1997-05-12 CN CNB971964599A patent/CN1163466C/zh not_active Expired - Fee Related
- 1997-05-12 TW TW086106284A patent/TW467892B/zh not_active IP Right Cessation
- 1997-05-12 CA CA002253869A patent/CA2253869C/en not_active Expired - Fee Related
- 1997-05-14 ID IDP971607A patent/ID20291A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE65998A1 (es) | 1998-10-20 |
| ZA974032B (en) | 1998-02-19 |
| ID20291A (id) | 1998-11-19 |
| CA2253869C (en) | 2003-04-22 |
| CN1163466C (zh) | 2004-08-25 |
| TNSN97085A1 (fr) | 2005-03-15 |
| YU18797A (en) | 1999-11-22 |
| HRP970246A2 (en) | 1998-04-30 |
| CO4990925A1 (es) | 2000-12-26 |
| MY132470A (en) | 2007-10-31 |
| TW467892B (en) | 2001-12-11 |
| AU3121997A (en) | 1997-12-05 |
| CN1225622A (zh) | 1999-08-11 |
| JPH11509870A (ja) | 1999-08-31 |
| AU727648B2 (en) | 2000-12-21 |
| SV1997000034A (es) | 1999-07-05 |
| WO1997043238A1 (en) | 1997-11-20 |
| HRP970246B1 (en) | 2002-04-30 |
| JP3417951B2 (ja) | 2003-06-16 |
| CA2253869A1 (en) | 1997-11-20 |
| PA8429401A1 (es) | 2000-05-24 |
| EP0912487A1 (en) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE89263T1 (de) | Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| ES2139943T3 (es) | Nuevos inhibidores de la sintasa de prostaglandina. | |
| ES536225A0 (es) | Un procedimiento para la preparacion de sulfamatos. | |
| ES2056810T3 (es) | Derivados de acido fosfinico. | |
| ATE25974T1 (de) | Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung. | |
| PT84654B (pt) | Processo para a preparacao de derivados de 4-h-1benzopirano-4-ona e de composicoes farmaceuticas que os contenham | |
| AR001999A1 (es) | Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion. | |
| AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas | |
| HN1997000067A (es) | Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz | |
| AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
| AR007097A1 (es) | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. | |
| AR007100A1 (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento. | |
| BR0008778A (pt) | Análogos de prostaglandinas seletivos para fpc16 insaturados | |
| RU98101090A (ru) | Моно- и дисульфозамещенные антрахиноны и их применение для лечения нарушений костного матрикса | |
| ECSP972115A (es) | Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz | |
| ECSP972112A (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido | |
| ECSP972111A (es) | Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos | |
| SV1997000038A (es) | Inhibicion de matrices metaloproteasas mediante acidos 2-(omega-aroilalkil)-4-biaril-4-oxobutirico | |
| MX9206042A (es) | Nuevos derivados de tiadiazinonas, proceso para su fabricacion y preparado farmaceutico que los contiene | |
| ECSP972114A (es) | Biarilacetilenos como inhibidores de la metaloproteasa de matriz | |
| NO963369D0 (no) | Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase | |
| ECSP972113A (es) | Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos | |
| FR2572074B1 (fr) | Derives du thiadiazole actifs sur le systeme nerveux central, procede d'obtention et compositions pharmaceutiques les contenant | |
| ATE29251T1 (de) | Aminopyridincarbonsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| BR112022015054A2 (pt) | Método para purificar 5-acetamido-n,n?-bis(2,3-di-hidroxipropil)-2,4,6-tri-iodoisofatalamida, e, 5-acetamido-n,n?-bis(2,3-di-hidroxipropil)-2,4,6-tri-iodoisofatalamida purificada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |